MYLOTARG 5mg powder for concentrate for solution for infusion

*
Pharmacy Only: Prescription
  • Company:

    Pfizer Healthcare Ireland
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 08 November 2023

File name

Adv SPC ML 10 0 IE clean.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 17 November 2022

File name

AdvSPCML90IEclean (2).pdf

Reasons for updating

  • Correction of spelling/typing errors
  • Removal of Black Inverted Triangle

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: removal of black triangle and editorial updates.

Updated on 17 November 2022

File name

ADVPILML100IENIclean (2).pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle
  • Correction of spelling/typing errors

Updated on 21 July 2022

File name

ADV PIL ML 9_0 IE NI clean.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Updated on 21 July 2022

File name

Adv SPC ML 8_0 IE clean.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 22 June 2022

File name

AdvSPCML70IEclean.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 20 April 2022

File name

ADVPILML80IENIclean.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 08 October 2021

File name

ADV PIL ML 7_0 IE & NI clean.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to MA holder contact details

Updated on 17 November 2020

File name

DEC202076369_ADV SPC ML 6_0 IE Clean.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.3 - Shelf life
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 17 November 2020

File name

DEC202076369_ADV PIL ML 6_0 IE Clean.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - manufacturer
  • Change to other sources of information section
  • Change to information for healthcare professionals

Updated on 30 April 2020

File name

DEC202027855_ADV PIL ML 5_0 UK IE CLEAN.pdf

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 25 October 2019

File name

DEC201958890_ADV SPC ML 5_0 UK IE_clean.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Other

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Text amended throughout according to QRD 10.. 

Updated on 25 October 2019

File name

DEC201958890_ADV PIL ML 4_0 UK IE_clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to information for healthcare professionals

Updated on 16 October 2019

File name

DEC201953275_ADV SPC ML 4_0 UK IE-clean.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Sections 4.8 and 5.1 updated to include information for paediatric refractory/relapsed AML.

Updated on 12 December 2018

File name

ADV PIL ML 3_0 UK IE clean.pdf

Reasons for updating

  • Change to section 6 - date of revision

Updated on 12 December 2018

File name

ADV SPC ML 3_0 UK IE clean.pdf

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: revision date only following change to annex A

Updated on 20 August 2018

File name

ADV PIL ML 2_0 UK IE clean.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 03 August 2018

File name

ADV SPC ML 2_0 UK IE clean.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 7 – Change to MAH

Section 10 – Date of revision of text

Updated on 04 May 2018

File name

ADV_SPC_ML_1_0_UK_IE.docx

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Product to be launched TBC actual date TBC ASAP, I will send an update when I have this date and please note PEARL will be updated on the launch date.

SPC:  

New SPC to reflect the new Pfizer Marketing Authorisation

PIL:   

New PIL to reflect the new Pfizer Marketing Authorisation

Packaging:    

New packaging to reflect the new Pfizer Marketing Authorisation

PI:

New PI to reflect the new Pfizer Marketing Authorisation

Updated on 26 April 2018

File name

ADV PIL ML 1_0 UK IE.pdf

Reasons for updating

  • New PIL for new product